Facing Lilly's competition, Novo's chief is pitching muscle preservation and broader health gains as the measure that matters in obesity treatment.
Recap by typeshit. Full story at 조선일보.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Healio
Researchers compared 22,694 first-time semaglutide users with 229,640 controls. Lead author Mille Dybdal Bager says the link shouldn't be read as cause and effect.
A short social post says quitting drugs like semaglutide does not ruin metabolism, while pointing to research on weight regain afterward.
Loading…